- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00652015
Molecular and Cellular Mechanisms of the In-stent-thrombosis
Molecular and Cellular Mechanisms of the In-stent-thrombosis. Is it Possible to Predict a In-stent-thrombosis Using Biomarkers?
Study Overview
Status
Detailed Description
In this prospective, open, not-randomized, controlled single-center pilot study 80 patients having had an in-stent-thrombosis (40 sub-acute thromboses (SAT), 40 late thromboses (LT)) and a control group of 80 patients having not developed a thrombosis will be compared.
The aim of this study is the establishment of diagnostic markers vor prediction of SAT (detection of CD39- and CD73-activity, respectively)and of LT (EPC-number and function, respectively) correspondingly aiming at the early identification of patients with high risk for developing an in-stent-thrombosis.
Study Type
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany, 52057
- RWTH University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients having developed an SAT or LT after stent implantation using PTCA
Exclusion Criteria:
- instabel coronary heart diseases,
- systemic autoimmune diseases,
- rheumatic diseases,
- tumors,
- impaired kidney or liver function,
- surgery within the last 3 months,
- pregnant or lactating women
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
|
|
2
Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The aim of this study is to establish diagnostic markers for prediction of SAT and LT, respectively, by identification of CD39 and CD73-activity and EPC-number and function, respectively.
Time Frame: may 08 to may 2010
|
may 08 to may 2010
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Burcin Özüyaman, MD, RWTH Aachen University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EK 039/08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With SAT or LT After Stent Implantation (PCI)
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruitingStent Thrombosis | Stent Restenosis | Chronic Coronary Syndrome | Clinical Outcome | Percutaneous Coronary Intervention (PCI) | Coronary Stent Implantation | MINOCA | Acute Coronary Syndromes (ACS) | INOCA (Ischemia With Non Obstructive Coronary Artery Disease)Italy
-
Cairo UniversityMohamed, Ahmed A., M.D.; Norhan Abdelaleem Ali; Hala Mostafa Gomaa; Shady Abo El...CompletedLiver Enzymes After General or Spinal Anesthetic Techniques | In Patients With Preoperatively Elevated Liver EnzymesEgypt
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment LinesItaly
-
Shanghai Tong Ren HospitalRecruitingAcute Coronary Syndrome Patients With Diabetes After PCIChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruitingConsented to Participate in the Trial and Signed an ICF | Patients With an Indication for PM Implantation or CRTPChina
-
Fudan UniversityRecruitingLymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)China
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationChina
-
The First Affiliated Hospital with Nanjing Medical...Xuzhou Central Hospital; Zhongda Hospital; The Affiliated Hospital of Xuzhou... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC) | Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or AblationChina
-
Novartis PharmaceuticalsCompletedIron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia MajorTurkey